Bone fragility: time to address the matrix
Abstract
Mechanical failure of bone—not bone density—is the primary clinical concern for skeletal disorders and diseases. Bone mass and density are major contributors to whole bone strength, which is why therapeutics that regulate bone volume by altering resorption and formation are so effective. However, there are limits to the increases in bone mass and density achieved with existing therapeutics and challenges in maintaining gains after treatment is suspended. This perspective focuses on a major contributor to whole bone strength that is not directly addressed by existing therapeutics: the quality of bone extracellular matrix as measured by matrix mechanical properties. We review studies showing: (1) whole bone strength is much more sensitive to variation in bone matrix quality than to bone mass/density, (2) bone matrix quality varies in humans in ways sufficient to influence whole bone strength, and (3) interventions may alter bone matrix quality with minimal effects on bone mass/density. A major limitation to discovering methods for improving bone matrix quality is that most preclinical studies focus on bone formation and bone density/mass and do not measure or report bone matrix mechanical properties. Identifying mechanisms that enhance bone matrix quality will require faster and more precise biomechanical assessments of bone matrix and studies specifying the molecular mechanisms that regulate the composition of bone extracellular matrix. While there are many observational reports of differences in bone matrix among individuals, here, we argue it is time to go beyond observational studies and consider bone matrix as an attractive therapeutic target.
Related
- GL-0001, a first-in-class dual GIP/GLP-2 analogue, reduces bone fragility by enhancing bone material properties in a murine model of type III osteogenesis imperfecta
- Cortical indices, DXA, and FRAX as indicators of bone fragility: a comparative human cadaveric study.
- Dietary Calcium Intake in Patients Evaluated for Bone Fragility, with a Focus on Women Receiving Adjuvant Endocrine Therapy for Breast Cancer: A Single-Center Cross-Sectional Study
- Effects of different anti-osteoporosis medications on re-fracture risk, bone mineral density, and functional recovery following hip fragility fracture surgery: a systematic review and network meta-analysis
- Clinical and bone-turnover outcomes associated with topical herbal plaster adjunctive therapy in older patients with myasthenia gravis and glucocorticoid-associated osteoporotic fragility fracture: a retrospective cohort study with exploratory peripheral-blood BMP-2/Smad/Runx2 analysis
BibTeX
@article{stephen2026bone,
title = {{Bone fragility: time to address the matrix}},
author = {Samuel J Stephen and Joy Y Wu and Christopher J Hernandez},
journal = {Journal of Bone and Mineral Research},
year = {2026},
month = jun,
doi = {10.1093/jbmr/zjag094},
url = {https://doi.org/10.1093/jbmr/zjag094},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Bone fragility: time to address the matrix
AU - Samuel J Stephen
AU - Joy Y Wu
AU - Christopher J Hernandez
PY - 2026
DA - 2026/06/09
JO - Journal of Bone and Mineral Research
DO - 10.1093/jbmr/zjag094
UR - https://doi.org/10.1093/jbmr/zjag094
AB - Mechanical failure of bone—not bone density—is the primary clinical concern for skeletal disorders and diseases. Bone mass and density are major contributors to whole bone strength, which is why therapeutics that regulate bone volume by altering resorption and formation are so effective. However, there are limits to the increases in bone mass and density achieved with existing therapeutics and challenges in maintaining gains after treatment is suspended. This perspective focuses on a major contributor to whole bone strength that is not directly addressed by existing therapeutics: the quality of bone extracellular matrix as measured by matrix mechanical properties. We review studies showing: (1) whole bone strength is much more sensitive to variation in bone matrix quality than to bone mass/density, (2) bone matrix quality varies in humans in ways sufficient to influence whole bone strength, and (3) interventions may alter bone matrix quality with minimal effects on bone mass/density. A major limitation to discovering methods for improving bone matrix quality is that most preclinical studies focus on bone formation and bone density/mass and do not measure or report bone matrix mechanical properties. Identifying mechanisms that enhance bone matrix quality will require faster and more precise biomechanical assessments of bone matrix and studies specifying the molecular mechanisms that regulate the composition of bone extracellular matrix. While there are many observational reports of differences in bone matrix among individuals, here, we argue it is time to go beyond observational studies and consider bone matrix as an attractive therapeutic target.
SN - 0884-0431
SN - 1523-4681
ER -